DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein

References

1. Arêas A. P. M., Oliveira M. L. S., Miyaji E. N., Leite L. C. C., Aires K. A., Dias W. O., Ho P. L. 2004; Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli : ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321:192–196 [CrossRef]
   [Google Scholar]
2. Arulanandam B. P., Lynch J. M., Briles D. E., Hollingshead S., Metzger D. W. 2001; Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69:6718–6724 [CrossRef]
   [Google Scholar]
3. Bogaert D., Hermans P. W. M., Adrian P. V., Rümke H. C., de Groot R. 2004; Pneumococcal vaccines: an update on current strategies. Vaccine 22:2209–2220 [CrossRef]
   [Google Scholar]
4. Borsage J. R., Watt J. M., McDaniel D. O., Swiatlo E., McDaniel L. S. 2001; Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae . Infect Immun 69:5456–5463 [CrossRef]
   [Google Scholar]
5. Brandileone M. C. C., Andrade A. L. S. S., Di Fabio J. L., Guerra M. L. L. S., Austrian R. 2003; Appropriateness of pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis 187:1206–1212 [CrossRef]
   [Google Scholar]
6. Briles D. E., Hollingshead S. K., King J., Swift A., Braun P. A., Park M. K., Ferguson L. M., Nahm M. H., Nabors G. S. 2000a; Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182:1694–1701 [CrossRef]
   [Google Scholar]
7. Briles D. E., Hollingshead S. K., Brooks-Walter A. & 7 other authors; 2000b; The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18:1707–1711 [CrossRef]
   [Google Scholar]
8. Chu R. S., Targoni O. S., Kried A. M., Lehmann P. V., Harding C. V. 1997; CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J Exp Med 186:1623–1631 [CrossRef]
   [Google Scholar]
9. Doria-Rose N. A., Haigwood N. L. 2003; DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 31:207–216 [CrossRef]
   [Google Scholar]
10. Klinman D. M., Yamshchikov G., Ishigatsubo Y. 1997; Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158:3635–3639
    [Google Scholar]
11. McDaniel L. S., Loechel F., Greenway T., Briles D. E., Conry R. M., Curiel D. T. 1997; Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae . Gene Ther 4:375–377 [CrossRef]
    [Google Scholar]
12. Miyaji E. N., Ferreira D. M., Lopes A. P. Y., Brandileone M. C. C., Dias W. O., Leite L. C. C. 2002; Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun 70:5086–5090 [CrossRef]
    [Google Scholar]
13. Miyaji E. N., Dias W. O., Tanizaki M. M., Leite L. C. C. 2003; Protective efficacy of pspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 37:53–54 [CrossRef]
    [Google Scholar]
14. Pelton S. I., Dagan R., Gaines B. M., Klugman K. P., Laufer D., O'Brien K., Schmitt H. J. 2003; Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 21:1562–1571 [CrossRef]
    [Google Scholar]
15. Ramos C. R., Abreu P. A., Nascimento A. L., Ho P. L. 2004; A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz J Med Biol Res 37:1103–1109
    [Google Scholar]
16. Ren B., Szalai A. J., Hollingshead S. K., Briles D. E. 2004; Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72:114–122 [CrossRef]
    [Google Scholar]
17. Shaper M., Hollingshead S. K., Benjamin W. H. Jr, Briles D. E. 2004; PspA protects Streptococcus pneumoniae from killing by apolactoferrin and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 72:5031–5040 [CrossRef]
    [Google Scholar]
18. Tu A. H., Fulgham R. L., McCrory M. A., Briles D. E., Szalai A. J. 1999; Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae . Infect Immun 67:4720–4724
    [Google Scholar]